This article is more than 5 years old. Information may no longer be current.
4DMT, Roche broaden research agreement for eye care products
Click Here to Manage Email Alerts
4DMT, a company focused on adeno-associated virus products for patients with severe genetic diseases, will lengthen its research agreement with Roche, according to a press release from 4DMT.
The continued partnership will allow the companies to develop and commercialize a variety of ophthalmic products.
“We have created clear synergies between 4D’s vector discovery, gene therapy development and manufacturing capabilities and Roche’s expertise in late-stage clinical development and global biologics commercialization,” David Kirn, MD, CEO and co-founder of 4DMT, said in the release. “The decision to expand our partnership represents validation of our ophthalmology platform, clinical candidates and team.”
Approximately 200,000 patients in the U.S. inherit retinal diseases, which are a leading cause of adult and childhood blindness. These conditions are known to be the result of gene mutations, but there are few approved therapies to treat them, according to the press release.